[Monoclonal Antibodies in the Treatment of XXXX in 2015].

@entity1 @entity786 @entity1072 @entity5805 @entity3118
Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of @entity1072 . Rituximab, the most widely used antiCD20 antibody in routine clinical practice, led not only to improvement of progressionfree survival, but also to improvement of overall survival in previously untreated @entity1 with good performance status in combination with @entity3118 and @entity786 . This regimen has become the standard treatment for @entity1 in good physical condition. Rituximab and the newest antiCD20 antibody obinutuzumab in combination with @entity5805 , as compared with @entity5805 alone, prolonged overall survival in previously untreated @entity1 with significant comorbidities, and the combination of antiCD20 antibody with @entity5805 has become the standard regimen in this group of @entity1 . Alemtuzumab and ofatumumab improved treatment results in @entity1072 . Targeted therapy with combination chemotherapy and monoclonal antibody in @entity1 with @entity1072 represents a significant advance in the treatment of this disease.Key words: monoclonal antibody - rituximab - ofatumumab - alemtuzumab - obinutuzumabThis study was supported by the program PRVOUK P27/LF1/1 and grant IGA-LF-2015-001.The authors declare they have no potential conflicts of interest concerning drugs, products, or   services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 28. 7. 2015Accepted: 2. 8. 2015.
